BIOMATRIX™ FAMILY

At each step of your patient's healing journey

Arterial Healing is a Journey

BIOSENSORS INTERNATIONAL™

BIOMATRIX™ FAMILY

We're at each step of your patient's healing journey

Haemostasis

Inflammation

Proliferation

Remodelling

BIOLIMUS A9™ DRUG

BIODEGRADABLE POLYMER

ABLUMINAL COATING

STENT PLATFORM

Bridging science and innovative technology for optimised arterial healing

The BIOMATRIX FAMILY favourably influences local wound healing processes[1-4]

Biosensors' Proprietary Limus Drug

Not all limus drugs are the same

- Biolimus A9™ (BA9™) is highly lipophilic versus other common limus drugs, with greater local bioavailability[1-4]
- BA9 exerts localized anti-inflammatory and anti-proliferative effects, reducing the risk of excessive neointimal thickening and restenosis[1-4]



BA9 elution time from the BIOMATRIX FAMILY of DES of at least six months ensures continuous anti-restenotic therapy for as long as the patient needs it[2,8-12,15]

Specifically Designed Polymer

Not all polymers are the same

- Biosensors' PLA polymer degrades to naturally occurring lactate over a 9-month period[2]
- Faster polymer degradation may not be optimal for wound healing[5]
- Lactate plays a key role in local wound healing processes, mainly via enhanced VEGF production[6,7]



The localized presence of PLA-derived lactate has the potential to facilitate arterial wound healing, including re-endothelialization[6-7]

The BIOMATRIX FAMILY is tailored to cover the healing journey of your patients[2,8-12]

In vivo Presence of BA9 and Biodegradation of PLA with Wound Healing Cascade Overlay†



† Pharmacokinetic data for BA9-eluting stent with biodegradable PLA polymer, derived from porcine models.

Designed to match the wound healing journey of real-world patients

BIOMATRIX™ FAMILY

The BIOMATRIX FAMILY offers added reassurance for a wide range of patient profiles, including potentially slow healers

Localised anti-restenotic therapy for at least six months[2]

- Every patient heals differently and it's not always possible to predict how long a particular patient will need anti-restenotic therapy
- Available data suggest that many DES-related lesions are likely to take more than 3 to 4 months to heal completely[9-12]

Predictors of slower wound healing include:[13-16]

- ► **More severe CAD** (e.g. ACS vs stable CAD)
- ► **Chronic disease** (e.g. PVD, cancer, diabetes)
- ► **Immunocompromising conditions**
- ► **Older age**
- ► **Certain medications** (e.g. glucocorticoids, NSAIDs, chemotherapy)
- ► **Poor nutritional status**
- ► **Obesity**
- ► **Smoking & alcoholism**

Proven broad-spectrum efficacy[17-19]

Efficacy extends to patients with severe CAD (e.g. ACS, multi-vessel disease, etc.), as well as individuals with diabetes:[2,17,18]

Outcomes in complex patients across clinical studies



POCE: Composition of all death, all MI, all revascularization; **MACE:** Composite of cardiac death, MI (target vessel MI in COMFORTABLE AMI study), ci-TVR.

ci-TVR: Clinically indicated Target Vessel Revascularization; **CD:** Cardiac Death; **STEMI:** ST-elevated Myocardial infarction; **IDDM:** Insulin-dependent Diabetes Mellitus; **CTO:** Chronic Total Occlusion; **RRR:** Relative Risk Reduction.

Data from LEADERS study; an 'all-comers' study, in which patients with stable CAD or an ACS were randomized to receive either a BIOMATRIX stent (n=857) or a sirolimus-eluting stent (SES, with durable polymer; n=850).[17,18]

Data from the COMFORTABLE AMI study, in which 1161 patients with ST-segment-elevation MI and undergoing primary PCI were randomized to receive either a BIOMATRIX stent or a bare metal stent.[19]

BIOMATRIX™ FAMILY

The preferred choice of DES for your patients

Many DES-related vessel lesions take more than 3 to 4 months to completely heal[9-12]

The BIOMATRIX FAMILY favourably influences local wound healing processes

- Highly localised delivery of anti-restenotic BA9™ for at least six months[1-4]
- Degradation of specifically designed PLA polymer to lactate, which has the potential to facilitate wound healing[2,6,7]

The BIOMATRIX FAMILY has proven efficacy in a broad range of patient types, including complex patients[17-19]

We're with your patients from start to finish

REFERENCES: **1.** BIOMATRIX NeoFlex, Instruction for use. Biosensors International. **2.** Data on File, Biosensors International. **3.** Grube E, Buellesfeld L. *Expert Rev Med Devices*. 2006;3:731-41. **4.** Abizaid A, Costa R. *Circ Cardiovasc Interv*. 2010;3:384-93. **5.** Bostman OM, J. *Bone Joint Surg Am*. 1991;73:148-53. **6.** Gladden LB. *J Physiol*. 2004;558(1):5-30. **7.** Ghani, QP. *et al*. *Methods in Enzymology*. 2004;381(36):565-75. **8.** Clark RA, In: Goldsmith, LA, ed. Physiology, biochemistry and molecular biology of the skin, 2nd Edition, Volume 1 (Oxford University Press; New York, 1991);p577. **9.** Lüscher TF, *et al*. *Circulation*. 2007;115:1051-58. **10.** Farb A, *et al*. *Circulation*. 2003;108:1701–06. **11.** Joner M, *et al*. *J Am Coll Cardiol*. 2006;48:193-202. **12.** De Cock D, *et al*. *Cardiovascular Imaging*. 2014;15:800-09. **13.** Räber L, *et al*. *International Journal of Cardiology*. 2014;173:259-67. **14.** Nakazawa G, *et al*. *Circulation*. 2008;118:1138-45. **15.** Hess CT. *Advan Skin Wound Care*. 2011;24:192. **16.** Guo S, DiPietro LA. *J Dent Res*. 2010;89:219-29. **17.** Windecker S *et al*. *Lancet*. 2008;372:1163-73. **18.** Serruys PW, *et al*. *JACC Cardiovasc Interv*. 2013;6:777-89. **19.** Räber L, *et al*. *Circ Cardiovasc Interv*. 2014;7:355-64.

LEADERS is a Biosensors International study. www.clinicaltrial.gov - NCT00389220. BioMatrix, Biolimus A9 and BA9 are trademarks or registered trademarks of Biosensors International Group, Ltd. All other cited trademarks are the property of their respective owners.

Not available for sale in the United States and certain other countries.

www.biosensors.com

BIOSENSORS INTERNATIONAL™

BIOSENSORS EUROPE SA
Rue de Lausanne 29
1110 Morges
Switzerland
Tel : +41(0)21 804 80 00
Fax: +41(0)21 804 80 01

BIOSENSORS INTERVENTIONAL TECHNOLOGIES PTE LTD
36 Jalan Tukang
Singapore 619266
Tel : +65 6213 5777
Fax: +65 6213 5737

11447-000-EN - Rev.01